This site is intended for US audiences only.
A treatment for the reduction of elevated IOP1
The first FDA-approved ROCK inhibitor that is believed to improve trabecular meshwork outflow1
Targets a main cause of elevated IOP
Most treatments lower IOP by decreasing aqueous humor production or by increasing outflow through the uveoscleral pathway, ignoring the normal outflow pathway through the trabecular meshwork.
Mechanism of Action
Rhopressa® is believed to work at the cellular level within the trabecular meshwork to improve outflow of aqueous humor4
promote actin-myosin contraction5
increase actin stress fibers and focal adhesions4
Rho kinase inhibitors
are believed to lower IOP by increasing aqueous humor outflow through the TM pathway4
Consistent IOP reduction across a range of baseline IOPs
Up to 5 mmHg IOP reduction in the three pivotal Phase 3 ROCKET studies6
Rocket baseline range: (> 17 to< 27/30 mmHg)
Study design: ROCKET 1, 2, 47, 8
ROCKET 1, ROCKET 2, and ROCKET 4 were double-masked, parallel, noninferiority Phase 3 studies of once-daily Rhopressa® 0.02% vs twice-daily timolol.
Ocular hypertension or open-angle glaucoma
Unmedicated baseline IOP (post-washout*):
ROCKET 1 & 2; >20 to <27 mmHg 8:00 AM and >17 to <27 mmHg 10:00 AM and 4:00 PM
ROCKET 4; >20 to <30 mmHg 8:00 AM and >17 to <30 mmHg 10:00 AM and 4:00 PM
ROCKET 1 (3-month duration)
Rhopressa® QD (n=202)
Timolol BID (n=209)
ROCKET 2 (12-month duration)
Rhopressa® QD (n=251)
Rhopressa® BID (n=254)
Timolol BID (n=251)
ROCKET 4 (6-month duration)
Rhopressa® QD (n=351)
Timolol BID (n=357)
Mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at Week 2, Week 6, and Month 3
Noninferiority margin (95% CI)
<1.5 mm at all time points vs timolol
<1.0 mm for a majority of all time points vs timolol
The minimum washout period was 4 weeks for patients using prostaglandin analogs or beta-adrenoceptor antagonists prior to study entry, 2 weeks for those using adrenergic agonists, and 5 days for those using muscarinic agonists.
Achieve consistent IOP reduction across a range of baseline IOPs
Patients treated with once-daily Rhopressa® experienced a reduction of IOP ranging from 3.9 mmHg to 4.1 mmHg6
Patients treated with twice-daily timolol experienced a reduction of IOP ranging from 3.5 mmHg to 4.6 mmHg6
In another clinical trial, Rhopressa® demonstrated further IOP reduction9
In the MERCURY-1 trial, conducted to support the approval of Rocklatan® (netarsudil and latanoprost opthalmic solution) 0.02%/0.005%, Rhopressa® further demonstrated mean IOP reduction up to 6.1 mmHg6
Phase 3 studies, MERCURY-1 and MERCURY-2 both included a wide range of baseline IOPs (>17 to <36 mmHg) vs ROCKET trials9,10
Study design: MERCURY-1 and MERCURY-29,10
MERCURY-1 (12-month) and MERCURY-2 (3-month) were double-masked, randomized, multicenter, active-controlled, parallel-group, Phase 3 studies of Rocklatan®, Rhopressa®, and latanoprost.
Age ≥18 years
Bilateral OAG or OHT
Unmedicated IOP (post-washout*):
>20 to <36 mmHg at 8:00 AM
>17 to <36 mmHg at 10:00 AM and 4:00 PM
MERCURY-1 (12-month duration, US only)
Rocklatan® QD (n=238)
Latanoprost QD (n=236)
Rhopressa® QD (n=244)
MERCURY-2 (3-month duration, US and Canada)
Rocklatan® QD (n=245)
Latanoprost QD (n=250)
Rhopressa® QD (n=255)
Mean IOP at 9 time points (8:00 AM, 10:00 AM, 4:00 PM at Week 2, Week 6, and Month 3)
The minimum washout period was 4 weeks for patients using prostaglandin analogs or beta-adrenoceptor antagonists prior to study entry, 2 weeks for those using adrenergic agonists, and 5 days for those using muscarinic agonists or carbonic anhydrase inhibitors.
Once-daily Rhopressa® is an innovative treatment option1
Safety profile established in >800 patients in Phase 3 pivotal Rocket studies7,8
Rhopressa® had minimal systemic AEs and no contraindications, and the majority of AEs were mild in Phase 3 trials7,8
The most common ocular AE observed in controlled clinical studies with Rhopressa® was conjunctival hyperemia, which was reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other ocular adverse reactions (~20%) in these clinical studies included cornea verticillata, instillation site pain, and conjunctival hemorrhage.1
Rhopressa® Savings Offer
Help Your Patients Save on Rhopressa®*
Eligible patients can reduce the cost of their prescription from the start with the Rhopressa® Savings Card.
with eligible commercial insurance where Rhopressa® is covered
with eligible commercial insurance where Rhopressa® is not covered
Download the Rhopressa® Savings Card and instruct patients to present it to the pharmacist with their prescription.Download the Rhopressa® Savings Card
Restrictions apply. Patients with State or Federal prescription coverage, such as Medicare or Medicaid, are excluded.See Terms and conditions
Patient Instructions: In order to redeem this offer you must have a valid prescription for Rocklatan® or Rhopressa®. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below. Patients who are enrolled in a state or federally funded prescription insurance program, such as Medicare or Medicaid, are excluded. Patients with questions about the Rocklatan® or Rhopressa® Savings offer should call 1-844-807-9706.
Eligible commercially insured patients with coverage for Rocklatan® or Rhopressa® will pay the first $25 per 30-day supply, maximum savings limit applies; patient out-of-pocket expense may vary. Offer valid up to 12 qualifying prescriptions.
Eligible commercially insured patients who are not covered for Rocklatan® or Rhopressa® will pay the first $50 per 30-day supply, maximum savings limit applies; patient out-of-pocket expense may vary. Offer valid for up to 6 qualifying prescriptions.
Pharmacist instructions for patients with commercial insurance coverage for Rocklatan® or Rhopressa®: Submit the claim to the primary commercial insurance company first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 8. The patient is responsible for the first $25. Reimbursement will be received from CHANGE HEALTHCARE.
Pharmacist instructions for patients with commercial insurance that are not covered: Submit this claim to CHANGE HEALTHCARE. A valid Other Coverage Code of 3 is required. The patient is responsible for the first $50. Reimbursement will be received from CHANGE HEALTHCARE.
For any questions regarding CHANGE HEALTHCARE online processing, please call the Help Desk 1-800-433-4893.
Restrictions: This offer is valid for eligible residents of the United States only. This offer is void in U.S. territories including, but not limited to, Puerto Rico. Offer not valid for prescriptions reimbursed under Medicare, a Medicaid drug benefit plan, TRICARE, CHAMPUS or other federal or state health programs. Offer may not be combined with any savings, discount, trial or similar offer for the same prescription. No other purchase is necessary. Coupon is not insurance. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. It is illegal to (or offer to) sell, purchase, trade, or counterfeit this offer. This offer is not transferable. Void where prohibited by law. Absent a change in Massachusetts law, for Massachusetts residents only, this offer will expire on December 31, 2019. Program managed by ConnectiveRx on behalf of Aerie Pharmaceuticals. Aerie Pharmaceuticals reserves the right to rescind, revoke or amend this offer without notice at any time.
A stronger eye care community
starts with you
VISIONaerieS® Program includes:
- Hearing from our thought leaders about glaucoma care
- Tools and resources to help your staff and patients better understand glaucoma
Sign up today!
For US eye care professionals only. All fields required.
1. Rhopressa [prescribing information]. Irvine, CA: Aerie Pharmaceuticals, Inc; 2019. 2. Asrani S, McKee H, Scott B, et al. Pooled Phase 3 efficacy analysis of a once-daily fixed dose combination of netarsudil 0.02% and latanoprost 0.005% in ocular hypertension and open-angle glaucoma. Presented at the 13th Biennial Meeting of the European Glaucoma Society, March 2018. 3. McLaren NC, Moroi SE. Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenetics J. 2003;3:197-210. 4. Wang SK, Chang RT. An emerging treatment option for glaucoma: rho kinase inhibitors. Clin Ophthalmol. 2014;8:883-890. 5. Mutsuki A, Masanori N, Kaibuchi K. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010;67(9):545-554. 6. Data on File, Aerie Pharmaceuticals, Inc. 7. Serle JB, Katz LJ, McLaurin E, et al; and ROCKET-1 and ROCKET-2 Study Groups. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127. 8. Khouri AS, Serle JB, Bacharach J, et al; for the ROCKET-4 Study Group. Once-daily netarsudil vs twice-daily timolol in patients with elevated intraocular pressure, the randomized Phase 3 ROCKET-4 study. Am J Ophthalmol. 2019. pii: S0002-9394(19)30098-4. doi: 10.1016/j.ajo.2019.03.002. [Epub ahead of print] PubMed PMID: 30862500. 9. Brubaker J, Teymoorian S, Lewis R, et al. Once-daily fixed-dose combination of netarsudil 0.02% and latanoprost 0.005% in ocular hypertension/open angle glaucoma: 12-month data from MERCURY-1. Presented at the 28th Meeting of the American Glaucoma Society, March 2018. 10. Walters T, Ahmed I, Lewis R, et al. Once-daily fixed-dose combination of netarsudil 0.02% and latanoprost 0.005% in ocular hypertension or open-angle glaucoma, the MERCURY-2 study. Presented at the 28th Meeting of the American Glaucoma Society, March 2018.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.
The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.
The corneal verticillata seen in Rhopressa®– treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.
Please click here for full prescribing information for Rhopressa®.
INDICATIONS AND USAGE
Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.